Objective: In the management of patients with severe acute lung injury and acute respiratory distress syndrome, clinicians are sometimes challenged to maintain acceptable gas exchange while avoiding harmful mechanical ventilation practices. In some of these patients, physicians may consider the use of "rescue therapies" to sustain life. Our goal is to provide a practical, evidence-based review to assist critical care physicians' care for patients with severe acute lung injury and acute respiratory distress syndrome.
A t the conclusion of this CME activity, participants will be able to distinguish effective rescue therapies for acute lung injury (ALI) and the indications to attempt them. In the management of patients with ALI and acute respiratory distress syndrome (ARDS), clinicians are sometimes challenged to maintain acceptable gas exchange while avoiding harmful mechanical ventilation practices. In some patients, life-threatening hypoxemia is caused by markedly elevated intrapulmonary shunt fraction. In others, dangerously elevated airway pressures are caused by severely reduced respiratory system compliance. Patients may have life-threatening respiratory acidosis caused by a markedly elevated pulmonary dead-space fraction. For these patients, clinicians may consider therapies that have the potential to improve gas exchange even though they may entail some risk and lack strong evidence for improving clinical outcomes; these have been termed "rescue therapies." However, "rescue" suggests that there are known beneficial effects. Future studies may demonstrate improved outcomes with some of these therapies. Until then, we prefer the term "unproven therapies." The goals of this article are to provide a practical approach to identifying severe ARDS and guide the use of unproven therapies on the basis of physiologic rationale, risks, and published evidence. Some of the clinical trials that we cite were underpowered for major outcomes, but they are still of value in guiding the use of therapies for severe ARDS.
DEFINITION
The lack of consensus regarding the definition of severe ARDS has limited our understanding of this subset of high-risk patients and impaired clinicians' ability to recognize and treat them effectively. Investigators from Canada and Australia defined severe ARDS as the presence of any one of the following criteria while receiving a lung-protective ventilation strategy: refractory hypoxemia defined as a PaO 2 of Ͻ60 mm Hg for at least 1 hr while receiving an FIO 2 of 1.0; refractory acidosis defined as a pH of Յ7.10 for at least 1 hr; or refractory barotraumas (1) . Because PaO 2 /FIO 2 has not been consistently associated with worse outcomes and varies with positive end-expiratory pressures (PEEPs), this criterion alone is not sufficient (2, 3) .
Investigators from the United Kingdom defined severe acute respiratory failure more comprehensively by using a lung injury score of Ն3.0 or uncompensated hypercapnea with a pH of Ͻ7.20 (4) . The lung injury score takes into account the distribution of chest radiograph abnormalities, the PaO 2 /FIO 2 , quasistatic respiratory compliance, and the level of PEEP. Another severity score based on lung morphology as determined by computed tomography revealed diffuse and hyperattenuated disease to be associated with a 75% mortality rate (5) .
In our opinion, patients with severe ARDS and at high risk for death should be identified promptly by first using a lung injury score of Ն3.0. When the application of a lung-protective ventilation strategy starts to fail in these patients because of severe gas-exchange abnormalities, excessively high plateau airway pressures (Ͼ30 -35 cm H 2 O), or severe respiratory acidosis, then treatment with unproven therapies should be considered (Table 1) . High plateau airway pressures are associated with higher mortality, but this relationship must vary with chest wall compliance, abdominal distension, and time with high plateau pressures. Therefore, we suggest a threshold range of 30 to 35 cm H 2 O to allow individual clinician judgment. For example, if a patient's chest wall compliance is estimated to be normal and plateau pressures have been elevated for several days, then the threshold of 30 cm H 2 O may be more reasonable than 35 cm H 2 O.
Initial Evaluation
Every patient should be evaluated for an underlying cause of ALI (especially sepsis, pneumonia, pancreatitis, transfusion-associated lung injury) and treated promptly (6 -9) . This evaluation includes a meticulous examination to look for occult sources of sepsis (e.g., deep soft tis-sue infections) and appropriate diagnostic testing (e.g., sterile samples for microbiological culture). If an underlying cause is not identified, then an alternative diagnosis (e.g., diffuse alveolar hemorrhage) should be considered, because some of these diagnoses can be treated with immunosuppressive agents. This evaluation may require invasive diagnostic testing (10, 11) . In addition, it may be helpful to perform transthoracic or transesophageal echocardiography to evaluate right and left ventricular function, cardiac filling pressures, and the presence or absence of right heart failure and a patent foramen ovale.
THERAPEUTIC STRATEGIES

Initial Interventions
A lung-protective ventilation strategy should be implemented immediately because of the excellent evidence that low tidal volume and low inspiratory pressure ventilation improve survival rates (2, 8, 12) . PEEP should be set at moderate levels by using the PaO 2 /FIO 2 grid used in the Respiratory Management in ALI/ARDS trial, the goal of which would be to obtain an oxygen saturation of approximately 90%. Tidal volumes as low as 4 mL/kg may be necessary to reach the goal plateau pressure of Ͻ30 cm H 2 O and avoid ventilator-associated lung injury. Achieving these low tidal volumes and low compliance may require the use of high respiratory rates, as long as intrinsic PEEP is not generated, and permissive hypercapnea. A fluid-conservative hemodynamic management strategy should be instituted if the patient is not in shock (mean systemic arterial pressure Ͼ60 mm Hg without vasopressor support) (13) . Real-time echocardiography may assist in the evaluation and management of acute cor pulmonale (14) . Lung injury score Ն3 (score is the sum of all components/number of components). Failing a lung-protective ventilation strategy because of any one of the following clinical parameters: refractory hypoxemia (O 2 saturation Ͻ90% for at least 1 hr on FIO 2 Ն0.80); refractory respiratory acidosis (pH Յ7.10 for at least 1 hr); and persistently elevated plateau airway pressures of Ͼ30 -35 cmH 2 O despite 4 -6 mL/kg predicted body weight tidal volume.
STRATEGIES FOR IMPROVING LIFE-THREATENING HYPOXEMIA
Recruitment Maneuvers and High PEEP
Rationale. A recruitment maneuver (RM) and high PEEP intend to aerate collapsed and flooded alveoli, which may improve oxygenation, decrease ventilator-induced lung injury from the shear stress of repetitive opening and closing of alveoli, and improve respiratory system compliance in some patients (15) . To do so, RMs use brief periods in which airway pressures are elevated and sustained at levels that are higher than those that result from tidal ventilation ( Table 2) .
Risks. High airway pressures may subject noncollapsed alveoli to overinflation, decreased alveolar fluid clearance, and additional ventilator-associated lung injury or may cause hemodynamic compromise (16) . High PEEP alone may provide similar benefits without subjecting the lungs to such high inspiratory pressures (17) . Two recent large clinical trials did not reveal increased use of vasopressors or neuromuscular blockade associated with an RM and/or high PEEP; however, that 22% of the patients who received RM experienced hypotension, arrhythmias, desaturation, or barotraumas was reported for one of these trials (1, 18) .
The Evidence
RM and High PEEP. Multiple observational studies have suggested that RM may be most effective early in the course of ARDS and for patients who have more severely impaired gas exchange, reduced compliance, increased dead-space ventilation, or diffuse disease (19, 20) .
Three large multicenter clinical trials compared the efficacy of a lung-protective ventilation strategy in combination with RM and/or high PEEP to lungprotective ventilation alone and found no significant difference in mortality rates (1, 18, 21) . However, the most recent trials did reveal significant benefits in multiple secondary outcomes (1, 18) .
In a trial conducted in Canada and Australia (the Lung Open Ventilation Study), the high PEEP plus RM study group underwent a 40-sec breath-hold at 40 cm H 2 0 and then had PEEP set at 20 cm H 2 0, with subsequent reductions according to a PEEP/FIO 2 grid (1). Results showed that the intervention group had fewer episodes of refractory hypoxemia (4.6% vs. 10.2%; p ϭ .01) and fewer deaths associated with refractory hypoxemia (4.2% vs. 8.9%; p ϭ .03).
In a trial performed in France (by the Expiratory Pressure Study Group, termed EXPRESS) the high-PEEP-treated group was treated with gradual increases in PEEP until the plateau airway pressures reached 28 to 30 cm H 2 O (18). The higher PEEP group had more ventilator-free days (medians of 7 vs. 3; p ϭ .04), more organ failurefree days (6 vs. 2; p ϭ .04), and a reduced use of rescue therapies for severe hypoxemia (18.7% vs. 34.6%; p Ͻ .001).
Clinical Application. RM with high PEEP or high PEEP alone should be considered early in the management of severe ARDS with life-threatening hypoxemia if plateau airway pressures are Ͻ30 cm H 2 0. Do not conduct RMs in patients who are in shock, who have pneumothorax, or in those with focal disease. Prepare the patient with adequate volume resuscitation and sedation to ensure patient-ventilator synchrony (8) . We recommend the use of the RM from the Lung Open Ventilation Study trial, because it demonstrated efficacy and safety in the largest number of patients (1) . Optimal PEEP should then be set approximately 5 to 10 cm H 2 0 above the pre-RM PEEP to maintain an open lung. When using high PEEP alone, the Assessment of Low tidal Volume and increased Endexpiratory volume to Obviate Lung Injury or EXPRESS protocols are reasonable approaches. It is important to assess for improvement in oxygenation and compliance immediately after the intervention and again within 6 to 12 hrs. If there is no improvement, then do not repeat RM. Also, abort the procedure if worsened hypoxemia or hypotension develops. If dead-space ventilation increases after the RM, then this suggests alveolar overdistension; therefore, the PEEP should be decreased.
Prone Positioning
Rationale. Prone positioning can promote recruitment of dependent, atelectatic lung regions most affected by ALI/ ARDS by relieving external compressive forces, thus improving ventilationperfusion matching without subjecting lungs to high airway pressures (22).
Risks. Safety data from randomized trials reveal infrequent local complications (e.g., facial edema, conjunctival hemorrhage, and pressure ulcers) and those attributable to turning (e.g., dislodging of catheters and endotracheal and thoracostomy tubes).
The Evidence. Although prone positioning has failed to demonstrate a survival benefit in hundreds of patients enrolled in four randomized, clinical trials, the two trials that placed patients prone for 20 hrs per day did report beneficial trends in mortality rates (23-26).
The initial trial, which failed to enroll the number of patients needed to detect the predetermined effect size, reported a trend for decreased intensive care unit mortality (43% vs. 58%; p ϭ .12) in the prone-treated group and significant improvements in oxygenation and plateau airway pressure when compared to the supine group (25). The subsequent trial compared protocolized delivery of prone position and lung-protective ventilation strategy to protocolized lung-protective ventilation strategy alone and reported similar low mortality levels in both groups (31% vs. 32.8%; p ϭ .72) (24). In Table 2 . Management strategy for life-threatening hypoxemia
Step 1. Measure plateau airway pressure. If Ͻ30 cm H 2 O, then proceed to Step 2a. If Ͼ30, then proceed to Step 2b. Step 2a. Implement a recruitment maneuver and/or high positive end-expiratory pressures alone.
Step 2b. Implement the prone position or high-frequency oscillatory ventilation.
Step 3. Evaluate effects on oxygenation, static compliance, and dead-space ventilation. If there is significant improvement, then continue with therapy. If there is no significant improvement, then proceed to the next intervention. Step 4. Administer inhaled nitric oxide; if no response within several hours, then proceed to the next intervention.
Step 5. Consider administration of glucocorticoids; weigh the risks and benefits for individual patients. Step 6. Consider extracorporeal life support. Candidates should not receive high-pressure ventilation for Ͼ7 days before extracorporeal life support. At each step, it is critical to evaluate effects on oxygenation, static compliance, and pulmonary dead-space ventilation. If there is significant improvement, then continue with therapy. If there is no significant improvement, then proceed to the next intervention.
patients with severe hypoxemia there was a trend toward a decreased 28-day mortality rate (37.8% vs. 46.1%; p ϭ .31) in the prone-treated group. Clinical Application. Consider placing patients prone if they have severe ARDS with life-threatening hypoxemia and/or elevated plateau airway pressures (Tables  2 and 4 ). Develop guidelines to prevent complications. Placing patients prone for a total of at least 20 hrs per day seems to be associated with greater benefit; however, intermittent time in the supine position may be necessary for nursing care and procedures. If there is no improvement in oxygenation by the end of the day, then do not continue with prone positioning and proceed promptly to another therapy (expert opinion).
High-Frequency Oscillatory Ventilation
Rationale. High-frequency oscillatory ventilation (HFOV) uses high mean airway pressure to achieve lung recruitment and improve oxygenation (27, 28). Ventilation is achieved with an oscillating piston that creates cycles of pressure above and below the mean airway pressure at a high frequency (180 -900/min), resulting in small tidal volumes (between 1 and 2.5 mL/kg).
Risks. Potential disadvantages are hemodynamic deterioration, barotraumas, or the need for heavy sedation and neuromuscular blockade to reduce ventilator asynchrony. In a large clinical trial, HFOV was not associated with more frequent episodes of intractable hypotension, air leak, or mucous plugging (27).
The Evidence. Several small retrospective studies of HFOV in patients with ARDS and severe hypoxemia and/or elevated plateau airway pressures have revealed significant improvements in oxygenation and suggested that early initiation may be associated with better outcomes (29, 30).
Two randomized trials have compared HFOV to conventional mechanical ventilation for safety and efficacy (27, 31). The initial trial terminated early because of poor patient accrual. The larger trial recruited 148 subjects with early ARDS and found a nonsignificant trend toward an improved 30-day mortality rate in the HFOV-treated group (37% vs. 52%; p ϭ .10), a temporary improvement in oxygenation, and an increase in PaCO 2 that did not significantly worsen pH (31). Large multicenter clinical trials are cur-rently being conducted by Canadian and British investigators to compare clinical outcomes of patients who receive HFOV to those who receive a conventional lungprotective ventilation strategy.
Clinical Application. We recommend HFOV early in the course of severe ARDS for patients with severe hypoxemia and/or elevated plateau airway pressures (Tables  2 and 4 ). HFOV should not be used in patients with shock, severe airway obstruction, intracranial hemorrhage, or refractory barotraumas; it must be used cautiously with severe acidosis, because CO 2 excretion may be limited. There are published protocols available for direction (32) .
Inhaled Nitric Oxide
Rationale and Risks. Inhaled nitric oxide (NO) induces vasodilatation in aerated portions of the lung, which may cause blood flow to redistribute toward ventilated areas, which results in improved oxygenation (33) (34) (35) (36) . It may also attenuate the activation of polymorphonuclear leukocytes and platelet aggregation (37) . However, when dissolved in alveolar fluid, NO may react with reactive oxygen species to form reactive nitrogen species, which can be cytotoxic to epithelial cells.
The Evidence and Risk. Several randomized clinical trials have failed to show a survival benefit for inhaled NO when compared to conventional mechanical ventilation alone (38 -40) . Approximately 60% of patients demonstrate improvement in oxygenation, which may last up to 4 days. Because the dose-response to inhaled NO may be unpredictable, these studies have been criticized (41) . A recently published meta-analysis of 12 randomized, controlled trials raised concerns regarding safety (42) . The metaanalysis revealed a trend toward increased mortality rates with the use of inhaled NO (n ϭ 1086; risk ratio, 1.10; 95% confidence interval, 0.94 -1.30) and a significantly increased risk for renal dysfunction (risk ratio, 1.50; 95% confidence interval, 1.11-2.02). The authors suggested that the prolonged administration of fixed dosing regimens may have subjected patients to the adverse effects of NO once the oxygenation improvement abated.
Clinical Application. Inhaled NO should be considered in patients with lifethreatening hypoxemia that failed previous interventions (Tables 2). Initiate inhaled NO at 1 ppm and titrate up every 30 mins until an improvement in oxygenation is observed, but not to exceed 10 ppm (35) . If there is no immediate response, then gradually discontinue its use. If there is a response, then the dose should be decreased daily to the lowest dose necessary to maintain the target oxygenation and should not be used for longer than 4 days.
Glucocorticoids
Rationale and Risks. Theoretically, glucocorticoids could halt the progression to severe and persistent ALI/ARDS by inhibiting neutrophil activation, fibroblast proliferation, and collagen deposition (43) (44) (45) . Large clinical trials of steroids in this population have suggested an increased incidence of serious neuromyopathic events in steroid-treated patients but no increased risk for infection as long as strict infection surveillance is implemented (46) . A subgroup analysis from the largest trial performed by the ARDS network investigators in 180 subjects with persistent ARDS revealed that subjects started on steroids after 14 days of diagnosis had an increased mortality rate (46) .
The Evidence. Clinical trials have failed to confirm a survival benefit for patients with early or persistent ALI/ ARDS who are treated with corticosteroids (46 -48) . Two small, randomized trials have examined the physiologic effects of corticosteroids in early hypoxemic respiratory failure attributable to ARDS (n ϭ 91) and severe pneumonia (n ϭ 46) and reported significant improvements in hypoxemia and lung injury scores observed as early as days 1 and 2 in the treatment group when compared to placebo and up to 1 wk (49, 50) .
Clinical Application. Consider corticosteroids for patients with life-threatening hypoxemia that has failed previous therapies. Corticosteroids should not be initiated after day 14 or in those who require or may require neuromuscular blockade. If corticosteroids are to be used, then we recommend the administration of methylprednisilone at low doses (1 mg/kg/ day), as was used in the Meduri et al trial (49) . Assess PaO 2 /FIO 2 , compliance, and PaCO 2 at baseline and on a daily basis. If no improvement occurs after 3 days, then discontinue treatment. If there is an improvement, then treatment can be extended, although the optimal duration is unknown. Seven days of therapy may be sufficient to improve oxygenation, al-though some investigators have raised concerns about discontinuing steroids too quickly, with a subsequent flare in inflammation and extubation failures. We suggest that physicians weigh the risks and benefits of prolonged treatment for their individual patients. Underlying infections should be treated appropriately, and strict infection surveillance should be implemented.
STRATEGIES FOR IMPROVING LIFE-THREATENING RESPIRATORY ACIDOSIS
Buffer Therapy
Rationale. Although permissive hypercapnea is a well-accepted practice, severe respiratory acidosis may deter some physicians from achieving the targets of a low-volume, low-pressure lung-protective ventilation strategy. Realistically, physicians may have varying thresholds for pH levels depending on the presence of shock or multiorgan failure. The urge to increase tidal volumes when plateau airway pressures are above target or when tidal volumes are already at 6 mL/kg should be resisted, because it may contribute to additional ventilator-associated lung injury (Table 3) .
The Evidence and Risks. Sodium bicarbonate infusions are commonly used in critical care units to manage lifethreatening acidosis, but during the buffering process, CO 2 is released, which raises the partial pressure of CO 2. In patients with impaired ventilation, this phenomenon may worsen acidosis (51) . Trishydroxymethyl aminomethane is a nonbicarbonate buffer that does not increase CO 2 production and in a small observational study improved pH and PaCO 2 in patients with ALI/ARDS and severe acidosis (52) . Tris-hydroxymethyl aminomethane infusion is contraindicated in patients with renal insufficiency; its risks include volume overload, hypoglycemia, and hyperkalemia.
Clinical Application. For life-threatening respiratory acidosis, tris-hydroxymethly aminomethane may be considered if there is no renal dysfunction. The dose is based on the base deficit, and glucose and potassium levels should be monitored. If tris-hydroxymethly aminomethane is contraindicated, then bicarbonate infusion may be used cautiously. Renal replacement therapies may be considered to assist with management of acidosis, particularly if other indications for renal replacement exist. If life-threatening acidosis persists, then tidal volumes can be increased by 1 to 2 mL/kg, and the patient should be considered promptly for extracorporeal life support (ECLS).
STRATEGY FOR REFRACTORY CASES ECLS
Rationale. ECLS for severe ALI/ARDS uses a veno-venous life-support circuit that removes blood from the patient and circulates it through a membrane oxygenator to relieve the lungs from their main function of gas exchange and allow the lungs to heal (Tables 2-4 ). In general, there are two types of ECLS that have been used to manage ARDS: extracorporeal membrane oxygenation (ECMO), a high-flow extracorporeal membraneoxygenation circuit, and extracorporeal carbon dioxide removal, a low-flow, mostly extracorporeal CO 2 -removal circuit (53) .
Risk. The use of ECLS is associated with significant risks, mostly because of the need for anticoagulation and large indwelling vascular access. Commonly reported complications include clots in circuit, hemorrhage at cannulation sites, and infection (54) .
The Evidence. Dismal outcomes in two older randomized, clinical trials of ECLS in severe ARDS were reported when compared with conventional ventilation (55, 56) . Subsequently published observational studies have reported survival rates ranging between 47% and 66% in select patients, including those on whom extracorporeal carbon dioxide removal was used (53, 54, (57) (58) (59) .
The Conventional Ventilation or ECMO for Severe Adult Respiratory Failure investigators recently published the results of their randomized, clinical trial of 180 subjects (60) . The ECLS group was transferred to a tertiary care hospital and treated with a protocol consisting of the prone position, lung-protective ventilation strategy, and microalbumin infusions, whereas the control group remained at their respective centers and were treated by nonprotocolized ventilator strategies. Of those transferred, only 77% received ECMO. Patients were excluded if they had received Ͼ7 days of high FIO 2 or high-pressure ventilation or had any contraindication to anticoagulation or continued treatment. The intervention group had an improvement in the composite end point of survival and absence of severe disability at 6 mos. However, the trial did not establish the value of ECMO itself but, rather, the value of transferring ill patients with ARDS to a regional center in the United Kingdom, which in turn might result in them receiving additional treatment, specifically lung-protective ventilation and/or other modalities including ECMO.
Clinical Application. We suggest that ECMO or possibly extracorporeal carbon dioxide removal be considered when patients are refractory to previously mentioned therapies. ECMO or extracorporeal carbon dioxide removal should be performed as part of a protocol at experienced medical centers. Do not consider its use for patients with contraindications to anticoagulation or for those who have been ventilated with high pressures for Ͼ1 wk (60).
CONCLUSIONS AND RECOMMENDATIONS
Caring for patients with severe ARDS is a major challenge. The goals of using unproven therapies for severe ARDS are to sustain life, minimize additional lung injury, and avoid placing the patient at excess risk for other nonpulmonary complications. Because physicians practice in a variety of hospital settings and healthcare systems, the local resources of expertise, technology, and finances will guide the use of unproven and newer investigational therapies.
Prompt recognition of patients with severe disease (lung injury score Ն3) who then have life-threatening hypoxemia, respiratory acidosis, or consistently elevated plateau airway pressures develop should trigger the early use of an unproven therapy.
For life-threatening hypoxemia, initial management with an RM and/or high PEEP should be undertaken if plateau airway pressures and lack of barotrauma allow. If not, or if these are not effective, then proceed to the prone position or HFOV. If hypoxemia still persists, then consider the administration of inhaled NO. If NO fails, then glucocorticoids can then be administered. For elevated plateau airway pressures when tidal volumes are 4 mL/kg, consider prone positioning or HFOV. For lifethreatening respiratory acidosis, consider the use of a buffer or continuous venovenous hemofiltration. It is most important to assess for objective physiologic improvement in the appropriate time period for each intervention. If no benefit is evident, then the therapy should be discontinued to minimize harm and delay in the initiation of another therapy. If the patient continues to have life-threatening hypoxemia, acidosis, or elevated plateau airway pressures, then consider ECMO or extracorporeal carbon dioxide removal. At the conclusion of this CME activity, participants will be able to identify effective rescue therapies for ALI and the indications to attempt them. 
